Filtered By:
Drug: Prozac

This page shows you your search results in order of date. This is page number 13.

Order by Relevance | Date

Total 193 results found since Jan 2013.

Antidepressant may help stroke patients with rehabilitation
Stephen FellerBALTIMORE, Sept. 2 (UPI) -- The antidepressant drug Prozac prolonged the amount of time after stroke that rehabilitation could restore movement and coordination in a study of mice.
Source: Health News - UPI.com - September 2, 2015 Category: Consumer Health News Source Type: news

Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence
ConclusionIn addition to the need of comprehensive‐clinical evidence, further elucidation of the beneficial mechanisms whereby SSRIs may improve structural and functional recovery from ischemic‐brain damage is needed to form a basis for translation into clinical practice. Several clinical studies have indicated that selective serotonin reuptake Inhibitors (SSRIs) administered after acute ischemic stroke can improve clinical recovery independently of depression. However, data from confirmatory trials in large study populations are lacking and the underlying mechanisms are incompletely understood. This review summarizes...
Source: Brain and Behavior - September 1, 2015 Category: Neurology Authors: Timo Siepmann, Ana Isabel Penzlin, Jessica Kepplinger, Ben Min‐Woo Illigens, Kerstin Weidner, Heinz Reichmann, Kristian Barlinn Tags: Review Source Type: research

Research in mice shows potential value of antidepressant in some stroke victims
Working with mice, researchers have added to evidence that a commonly prescribed antidepressant called fluoxetine helps stroke victims improve movement and coordination, and possibly why.
Source: ScienceDaily Headlines - August 31, 2015 Category: Science Source Type: news

The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: a study protocol for three multicentre randomised controlled trials
DiscussionIf fluoxetine is safe and effective in promoting functional recovery, it could be rapidly, widely and affordably implemented in routine clinical practice and reduce the burden of disability due to stroke.Trial registrationFOCUS: ISRCTN83290762 (23/05/2012), AFFINITY: ACTRN12611000774921 (22/07/2011). EFFECTS: ISRCTN13020412 (19/12/2014).
Source: Trials - August 20, 2015 Category: Journals (General) Authors: Gillian MeadMaree HackettErik LundströmVeronica MurrayGraeme HankeyMartin Dennis Source Type: research

Pathological Laughing: Brain SPECT Findings
We present the case of a 40-year-old man consulting for uncontrollable episodes of laughing related to emotional lability and not systematically linked to feelings of happiness. Seven months earlier he had presented a pontine ischemic stroke related to an occlusion of the basilar and left vertebral arteries. No epileptic activity or new MRI brain lesions were found. Brain perfusion SPECT performed showed marked hypoperfusion in the right frontal inferior and temporoinsular regions, suggesting a diaschisis phenomenon caused by pontine lesions and highlighted laughing regulation pathways. The patient was successfully treated...
Source: Clinical Nuclear Medicine - August 11, 2015 Category: Nuclear Medicine Tags: Interesting Images Source Type: research

Fluoxetine enhanced neurogenesis is not translated to functional outcome in stroke rats
Publication date: 31 August 2015 Source:Neuroscience Letters, Volume 603 Author(s): Xiaoyu Sun, Xuan Sun, Tingting Liu, Mei Zhao, Shanshan Zhao, Ting Xiao, Jukka Jolkkonen, Chuansheng Zhao Fluoxetine is widely used in clinical practice. It regulates hippocampal neurogenesis, however, the effect of fluoxetine on neurogenesis in the subventricular zone (SVZ) remains controversial. We aimed to study the effect of fluoxetine on neurogenesis in the SVZ and subgranular zone (SGZ) of dentate gyrus (DG) in relation to behavioral recovery after stroke in rats. Adult male Wistar rats were randomly assigned to four groups: ...
Source: Neuroscience Letters - July 25, 2015 Category: Neuroscience Source Type: research

Interventions for post-stroke fatigue.
CONCLUSIONS: There was insufficient evidence on the efficacy of any intervention to treat or prevent fatigue after stroke. Trials to date have been small and heterogeneous, and some have had a high risk of bias. Some of the interventions described were feasible in people with stroke, but their efficacy should be investigated in RCTs with a more robust study design and adequate sample sizes. PMID: 26133313 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - July 2, 2015 Category: Journals (General) Authors: Wu S, Kutlubaev MA, Chun HY, Cowey E, Pollock A, Macleod MR, Dennis M, Keane E, Sharpe M, Mead GE Tags: Cochrane Database Syst Rev Source Type: research

Effectiveness and safety of Wuling capsule for post stroke depression: A systematic review.
CONCLUSION: Wuling capsule appeared to present certain antidepressant effect compared to no treatment control. With a combination of several Western medicines, Wuling capsule could be helpful in strengthening efficacy and reducing the incidence of adverse events as an alternative choice in the treatment of PSD. However, due to the limited number of included trials and relatively moderate methodological quality in the majority of studies, further large scale and rigorously designed trials are warranted to confirm the effectiveness and safety of Wuling capsule for post stroke depression. PMID: 24906594 [PubMed - as supplied by publisher]
Source: Complementary Therapies in Medicine - June 1, 2014 Category: Complementary Medicine Authors: Peng L, Zhang X, Kang DY, Liu XT, Hong Q Tags: Complement Ther Med Source Type: research

Protein-Drug Interactome Analysis of SSRI-mediated Neurorecovery following Stroke.
Abstract Serotonin selective reuptake inhibitors (SSRIs) have been widely used as first-line drugs in the treatment of a range of depressive and anxiety disorders. Recently, clinical studies found that this class of agents also shows significant efficacy in promoting neurogenesis, neuroplasticity and neurorecovery following stroke. Here, we attempt to elucidate molecular mechanism and biological implication underlying the SSRI-mediated neurorecovery. In the procedure, a comprehensive protein-drug interactome (PDI) was constructed for various SSRIs and their major metabolites as well as a group of control drugs acr...
Source: Biosystems - April 3, 2014 Category: Biotechnology Authors: Chen HF, Pan XL, Wang JW, Kong HM, Fu YM Tags: Biosystems Source Type: research

Fluoxetine enhances Brain Derived Neurotropic Factor Serum Concentration and Cognition in Patients with Vascular Dementia.
Abstract Selective serotonin reuptake inhibitors (SSRIs) improve cognition in patients with stroke and increase the expression of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. However, the effects of SSRIs on cognition and BDNF level in vascular dementia (VaD) patients are largely unknown. We performed an open-label study to investigate the effects of fluoxetine, a selective serotonin reuptake inhibitor, on mini-mental state examination (MMSE) score and serum BDNF level in VaD patients. Fifty VaD patients were randomly allocated to receive fluoxetine (20 mg/d; n = 25) or no fluoxetine (control g...
Source: Current Neurovascular Research - August 19, 2013 Category: Neurology Authors: Liu X, Zhang J, Sun D, Fan Y, Zhou H, Fu B Tags: Curr Neurovasc Res Source Type: research

Treating post-stroke depression with Xingnao Jieyu capsules or fluoxetine
The occurrence of post-stroke depression results from the effects of biological, psychological, and social factors, likely involving neurotransmitters, neuroendocrine effects, nerve anatomy, neurotrophic factors, neural regeneration, inflammatory reactions, and social psyche factors. Synaptotagmin promotes neurotransmitter release, regulates the transfer of synaptic vesicle to synaptic active zones, and is a key factor in information transfer among neurons. The Xingnao Jieyu capsule has been shown to effectively relieve neurologic impairments and lessen depression...
Source: Health News from Medical News Today - August 16, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Xingnao Jieyu capsules are similar to fluoxetine for post-stroke depression
(Neural Regeneration Research) Xingnao Jieyu capsules are similar to fluoxetine for post- stroke depression.
Source: EurekAlert! - Medicine and Health - August 14, 2013 Category: Global & Universal Source Type: news